Press Release: Nucleix : Nucleix Receives Reimbursement for Bladder EpiCheck in the Netherlands

SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced it has been informed it will receive national reimbursement approval from The Dutch Healthcare Authority (NZA) in the Netherlands, effective January 1, 2024, for its CE-marked Bladder EpiCheck® test for detection of primary or recurrent bladder cancer and upper tract urinary cancer. "Until now, the Dutch NMIBC Care Path included only c